Zydelig (idelalisib; Gilead) Drug Overview & Product Profiles 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Zydelig” report has been added to ResearchAndMarkets.com’s offering.

Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis. Further studies have shown that Zydelig not only causes cell death, but also reduces the interactions that retain chronic lymphocytic leukemia (CLL) cells in protective microenvironments.

Analyst Outlook

Zydelig (idelalisib; Gilead) is the first selective inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) approved for the follicular lymphoma (FL) market. Demonstrating efficacy in previously treated FL patients who are refractory to both Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) and alkylating agents, Zydelig gained approval in the US and EU as a single agent for relapsed FL patients who have received at least two prior therapies (Zydelig prescribing information, 2014).

Although this satisfied a significant unmet need within the FL market, larger commercial success of Zydelig depended on future potential label expansions to earlier lines of treatment as a combination therapy. However, the two ongoing Phase III trials of Zydelig in the second-line treatment setting, in combination with Rituxanin and Rituxan plus Treanda (bendamustine; Teva) (ClinicalTrials.gov identifiers: NCT01732913 and NCT01732926, respectively) were put on hold.

Gilead suspended the trials after the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) initiated reviews of Zydelig in March 2016 following an observed increased rate of serious adverse advents in clinical trials of the drug in combination with other cancer medicines (EMA press release, 2016; FDA Drug Safety Announcement, 2016). This hold on combination trials of Zydelig potentially limits its growth opportunities in the FL market.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Zydelig: Chronic lymphocytic leukemia (CLL)

Zydelig: NHL: Follicular lymphoma (FL)

LIST OF FIGURES

Figure 1: The authors drug assessment summary of Zydelig for CLL

Figure 2: Zydelig sales for CLL across the US and five major EU markets, by country, 2017-26

Figure 3: Zydelig for follicular lymphoma – SWOT analysis

Figure 4: The authors drug assessment summary of Zydelig for follicular lymphoma

Figure 5: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country, 2017-26

LIST OF TABLES

Table 1: Zydelig drug profile

Table 2: Approval history of Zydelig for CLL in the US, Japan, and five major EU markets

Table 3: Trials of Zydelig for CLL

Table 4: Zydelig for CLL – SWOT analysis

Table 5: Zydelig drug profile

Table 6: Zydelig pivotal trial data in follicular lymphoma

Table 7: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/mea68k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Leukemia Drugs , Lymphoma Drugs